Cybin reports fiscal year 2024 financial results and recent business highlights

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental health disorders, today reported audited financial results for its fiscal year ended march 31, 2024, and recent business highlights. “i am proud of the swift and meaningful progress we have made advancing our two lead programs – c.
CYBN Ratings Summary
CYBN Quant Ranking